Compare · MDLN vs NVCR
MDLN vs NVCR
Side-by-side comparison of Medline Inc. (MDLN) and NovoCure Limited (NVCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVCR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.05B, about 22.4x NVCR ($2.06B).
- Over the past year, MDLN is down 13.1% and NVCR is up 42.0% - NVCR leads by 55.1 points.
- MDLN has been more active in the news (5 items in the past 4 weeks vs 1 for NVCR).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- NovoCure Limited
- Price
- $35.41+1.10%
- $17.31-2.01%
- Market cap
- $46.05B
- $2.06B
- 1M return
- -12.52%
- +13.03%
- 1Y return
- -13.12%
- +42.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 25
NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest NVCR
- NovoCure Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by NovoCure Limited
- Novocure Reports Second Quarter 2026 Financial Results
- Analyst resumed coverage on NovoCure with a new price target
- Chief Human Resources Officer Puri Michal Nath was granted 1,905 units of Ordinary Shares, increasing direct ownership by 0.95% to 203,227 units (SEC Form 4)
- Chief Executive Officer Leonard Frank X was granted 1,905 units of Ordinary Shares, increasing direct ownership by 0.41% to 461,425 units (SEC Form 4)
- General Counsel Ben Arye Barak was granted 1,299 units of Ordinary Shares, increasing direct ownership by 0.54% to 243,752 units (SEC Form 4)
- Director Danziger Asaf was granted 268 units of Ordinary Shares, increasing direct ownership by 0.06% to 416,742 units (SEC Form 4)
- Novocure to Report Second Quarter 2026 Financial Results